Member States to evaluate 107 substances in 2018-2020
ECHA proposes to include 107 substances in the Community rolling action plan (CoRAP) for 2018-2020 to be evaluated by the Member States. If you have registered these substances, you should coordinate your actions with your co-registrants and contact the evaluating authority.
Helsinki, 24 October 2017 - 26 substances are expected to be evaluated in 2018, 37 in 2019 and 44 in 2020. ECHA encourages registrants of the listed substances to start coordinating their actions and to contact the evaluating authorities in the Member States. Downstream users of the listed substances are invited to review the information they hold and share that with registrants.
In particular, it is important that use and exposure scenarios as well as the exposure estimations are up-to-date and clearly documented within the chemical safety reports of the registrants. For the 26 substances to be evaluated in 2018, dossier updates, where relevant, should be made before March 2018.
The draft CoRAP includes the non-confidential substance names, CAS and EC numbers, the tentative year of evaluation, contact details of the proposed evaluating Member State as well as a brief indication of the initial area of concern. This year, the groups of structurally similar substances that potentially could be evaluated together are also marked in the plan.
The list has been prepared together with the Member States, taking into account risk-based criteria to select the substances. The final plan will be adopted in March 2018.
ECHA’s Member State Committee will discuss the draft CoRAP this week and will prepare an opinion on the draft plan in February 2018. Based on the opinion, ECHA will adopt the final CoRAP update for 2018-2020 and publish it in March 2018. From the publication, the Member States will have one year to evaluate the substances specified for 2018. Where necessary, they will prepare a draft decision to request further information from registrants to clarify the concerns.
Member States evaluate certain substances to clarify whether their use poses a risk to human health or the environment. The objective is to request further information from the registrants of the substance to verify the suspected concern, if necessary. The evaluation may conclude that the risks are sufficiently under control with the measures already in place. Otherwise, it may lead to the proposal of EU-wide risk management measures such as restrictions, identification of substances of very high concern, harmonised classification or other actions.